Skip to main content
Top
Published in: Endocrine Pathology 3/2015

01-09-2015

Comparison of Three Ki-67 Index Quantification Methods and Clinical Significance in Pancreatic Neuroendocrine Tumors

Authors: Trynda N. Kroneman, Jesse S. Voss, Christine M. Lohse, Tsung-Teh Wu, Thomas C. Smyrk, Lizhi Zhang

Published in: Endocrine Pathology | Issue 3/2015

Login to get access

Abstract

The Ki-67 index is essential in the pathological reports for pancreatic neuroendocrine tumors. There are three methods to determine the Ki-67 index including eyeball estimation, manual counting, or automated digital imaging analysis. The goal of this study was to compare the three quantification methods with the clinical outcome to determine the best method for clinical practice. Ki-67 immunostaining was performed on 97 resected pancreatic neuroendocrine tumors. The three methods of quantification were employed: (1) an average of eyeball estimation by three pathologists; (2) manual counting of at least 500 tumor cells; and (3) digital imaging analysis quantitation by selecting 8–10 hot spot regions. All tumors were graded according to the 2010 WHO grading system. The three quantification methods for the Ki-67 index had almost perfect agreement. The concordance between manual counting and digital imaging analysis and between manual counting and average eyeball estimation were 0.97 and 0.88, respectively. The concordance among the three pathologists’ eyeball estimation was 0.86. All three methods correlated with patients’ survival using the 2010 WHO grading system. Eyeball estimation scores were significantly less than those of the other two methods and tended to downgrade more tumors to grade 1, but they had higher predictive ability for survival and recurrence. The WHO system using the mitotic rate could also separate patients with different survival and even downgraded more tumors to grade 1. The results suggest the necessity of a consensus among pathologists for the method to determine the Ki-67 index and proper cutoff of the Ki-67 index for better clinical correlation.
Literature
1.
go back to reference Ferrone CR, Tang LH, Tomlinson J, Gonen M, Hochwald SN, Brennan MF, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol. 2007;25(35):5609–15.PubMedCrossRef Ferrone CR, Tang LH, Tomlinson J, Gonen M, Hochwald SN, Brennan MF, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol. 2007;25(35):5609–15.PubMedCrossRef
2.
go back to reference Jamali M, Chetty R. Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocrine pathology. 2008;19(4):282–8.PubMedCrossRef Jamali M, Chetty R. Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocrine pathology. 2008;19(4):282–8.PubMedCrossRef
3.
go back to reference La Rosa S, Klersy C, Uccella S, Dainese L, Albarello L, Sonzogni A, et al. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol. 2009;40(1):30–40.PubMedCrossRef La Rosa S, Klersy C, Uccella S, Dainese L, Albarello L, Sonzogni A, et al. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol. 2009;40(1):30–40.PubMedCrossRef
4.
go back to reference Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. 2010;23(6):824–33.PubMedCrossRef Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. 2010;23(6):824–33.PubMedCrossRef
5.
go back to reference Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20(11):2633–42.PubMedCrossRef Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20(11):2633–42.PubMedCrossRef
6.
go back to reference Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch. 1995;425(6):547–60.PubMedCrossRef Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch. 1995;425(6):547–60.PubMedCrossRef
7.
go back to reference Zhang L, Lohse CM, Dao LN, Smyrk TC. Proposed histopathologic grading system derived from a study of KIT and CK19 expression in pancreatic endocrine neoplasm. Hum Pathol. 2011;42(3):324–31.PubMedCrossRef Zhang L, Lohse CM, Dao LN, Smyrk TC. Proposed histopathologic grading system derived from a study of KIT and CK19 expression in pancreatic endocrine neoplasm. Hum Pathol. 2011;42(3):324–31.PubMedCrossRef
8.
go back to reference DeLellis RA LR, Heitz PU, and Eng C. Pathology & Genetics, Tumors of Endocrine Organs 2004. DeLellis RA LR, Heitz PU, and Eng C. Pathology & Genetics, Tumors of Endocrine Organs 2004.
9.
go back to reference Rindi G, de Herder WW, O'Toole D, Wiedenmann B. Consensus guidelines for the management of patients with digestive neuroendocrine tumors: why such guidelines and how we went about It. Neuroendocrinology. 2006;84(3):155–7.PubMedCrossRef Rindi G, de Herder WW, O'Toole D, Wiedenmann B. Consensus guidelines for the management of patients with digestive neuroendocrine tumors: why such guidelines and how we went about It. Neuroendocrinology. 2006;84(3):155–7.PubMedCrossRef
10.
go back to reference Yamaguchi T, Fujimori T, Tomita S, Ichikawa K, Mitomi H, Ohno K, et al. Clinical validation of the gastrointestinal NET grading system: Ki67 index criteria of the WHO 2010 classification is appropriate to predict metastasis or recurrence. Diagn Pathol. 2013;8:65.PubMedCentralPubMedCrossRef Yamaguchi T, Fujimori T, Tomita S, Ichikawa K, Mitomi H, Ohno K, et al. Clinical validation of the gastrointestinal NET grading system: Ki67 index criteria of the WHO 2010 classification is appropriate to predict metastasis or recurrence. Diagn Pathol. 2013;8:65.PubMedCentralPubMedCrossRef
11.
go back to reference Bosman F, Carneiro F, Hruban R, Theise N. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer; 2010. Bosman F, Carneiro F, Hruban R, Theise N. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer; 2010.
12.
go back to reference Adsay V. Ki67 labeling index in neuroendocrine tumors of the gastrointestinal and pancreatobiliary tract: to count or not to count is not the question, but rather how to count. The American journal of surgical pathology. 2012;36(12):1743–6.PubMedCrossRef Adsay V. Ki67 labeling index in neuroendocrine tumors of the gastrointestinal and pancreatobiliary tract: to count or not to count is not the question, but rather how to count. The American journal of surgical pathology. 2012;36(12):1743–6.PubMedCrossRef
13.
go back to reference Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, O'Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen CY, Washington MK, Wiedenmann B, Yao J. Pathology Reporting of Neuroendocrine Tumors: Application of the Delphic Consensus Process to the Development of a Minimum Pathology Data Set. Am J Surg Pathol 2010;34(3):300–13PubMedCrossRef Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, O'Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen CY, Washington MK, Wiedenmann B, Yao J. Pathology Reporting of Neuroendocrine Tumors: Application of the Delphic Consensus Process to the Development of a Minimum Pathology Data Set. Am J Surg Pathol 2010;34(3):300–13PubMedCrossRef
14.
go back to reference Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449(4):395–401.PubMedCentralPubMedCrossRef Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449(4):395–401.PubMedCentralPubMedCrossRef
15.
go back to reference Reid MD, Bagci P, Ohike N, Saka B, Erbarut Seven I, Dursun N, et al. Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. Mod Pathol. 2015;28(5):686–94.PubMedCentralPubMedCrossRef Reid MD, Bagci P, Ohike N, Saka B, Erbarut Seven I, Dursun N, et al. Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. Mod Pathol. 2015;28(5):686–94.PubMedCentralPubMedCrossRef
16.
go back to reference Zhang L, Smyrk TC, Oliveira AM, Lohse CM, Zhang S, Johnson MR, et al. KIT is an Independent Prognostic Marker for Pancreatic Endocrine Tumors: A Finding Derived From Analysis of Islet Cell Differentiation Markers. Am J Surg Pathol. 2009;33(10):1562–9.PubMedCrossRef Zhang L, Smyrk TC, Oliveira AM, Lohse CM, Zhang S, Johnson MR, et al. KIT is an Independent Prognostic Marker for Pancreatic Endocrine Tumors: A Finding Derived From Analysis of Islet Cell Differentiation Markers. Am J Surg Pathol. 2009;33(10):1562–9.PubMedCrossRef
17.
go back to reference Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45(1):255–68.PubMedCrossRef Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45(1):255–68.PubMedCrossRef
18.
go back to reference Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statistics in medicine. 1996;15(4):361–87.PubMedCrossRef Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statistics in medicine. 1996;15(4):361–87.PubMedCrossRef
19.
go back to reference McCall CM, Shi C, Cornish TC, Klimstra DS, Tang LH, Basturk O, et al. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. The American journal of surgical pathology. 2013;37(11):1671–7.PubMedCentralPubMedCrossRef McCall CM, Shi C, Cornish TC, Klimstra DS, Tang LH, Basturk O, et al. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. The American journal of surgical pathology. 2013;37(11):1671–7.PubMedCentralPubMedCrossRef
20.
go back to reference Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014;120(18):2814–23.PubMedCrossRef Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014;120(18):2814–23.PubMedCrossRef
21.
go back to reference Khan MS, Luong TV, Watkins J, Toumpanakis C, Caplin ME, Meyer T. A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. British journal of cancer. 2013;108(9):1838–45.PubMedCentralPubMedCrossRef Khan MS, Luong TV, Watkins J, Toumpanakis C, Caplin ME, Meyer T. A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. British journal of cancer. 2013;108(9):1838–45.PubMedCentralPubMedCrossRef
22.
go back to reference Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. The American journal of surgical pathology. 2012;36(12):1761–70.PubMedCrossRef Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. The American journal of surgical pathology. 2012;36(12):1761–70.PubMedCrossRef
23.
go back to reference Klapper W, Hoster E, Determann O, Oschlies I, van der Laak J, Berger F, et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. Journal of Hematopathology. 2009;2(2):103–11.PubMedCentralPubMedCrossRef Klapper W, Hoster E, Determann O, Oschlies I, van der Laak J, Berger F, et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. Journal of Hematopathology. 2009;2(2):103–11.PubMedCentralPubMedCrossRef
24.
go back to reference Schwartz BR, Pinkus G, Bacus S, Toder M, Weinberg DS. Cell proliferation in non-Hodgkin's lymphomas. Digital image analysis of Ki-67 antibody staining. The American journal of pathology. 1989;134(2):327–36.PubMedCentralPubMed Schwartz BR, Pinkus G, Bacus S, Toder M, Weinberg DS. Cell proliferation in non-Hodgkin's lymphomas. Digital image analysis of Ki-67 antibody staining. The American journal of pathology. 1989;134(2):327–36.PubMedCentralPubMed
25.
go back to reference Walts AE, Ines D, Marchevsky AM. Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors. Mod Pathol. 2012; 25 (9): 1258–64.PubMedCrossRef Walts AE, Ines D, Marchevsky AM. Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors. Mod Pathol. 2012; 25 (9): 1258–64.PubMedCrossRef
26.
go back to reference Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol. 2011;35(6):853–60.PubMedCrossRef Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol. 2011;35(6):853–60.PubMedCrossRef
27.
go back to reference Nielsen PS, Riber-Hansen R, Raundahl J, Steiniche T. Automated Quantification of MART1-Verified Ki67 Indices by Digital Image Analysis in Melanocytic Lesions. Archives of pathology & laboratory medicine. 2012;136(6):627–34.CrossRef Nielsen PS, Riber-Hansen R, Raundahl J, Steiniche T. Automated Quantification of MART1-Verified Ki67 Indices by Digital Image Analysis in Melanocytic Lesions. Archives of pathology & laboratory medicine. 2012;136(6):627–34.CrossRef
28.
go back to reference Tuominen VJ, Ruotoistenmaki S, Viitanen A, Jumppanen M, Isola J. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res. 2010;12(4):R56.PubMedCentralPubMedCrossRef Tuominen VJ, Ruotoistenmaki S, Viitanen A, Jumppanen M, Isola J. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res. 2010;12(4):R56.PubMedCentralPubMedCrossRef
29.
go back to reference Dhall D, Mertens R, Bresee C, Parakh R, Wang HL, Li M, et al. Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors. Hum Pathol. 2012;43(4):489–95.PubMedCrossRef Dhall D, Mertens R, Bresee C, Parakh R, Wang HL, Li M, et al. Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors. Hum Pathol. 2012;43(4):489–95.PubMedCrossRef
30.
go back to reference Goedkoop AY, de Rie MA, Teunissen MB, Picavet DI, van der Hall PO, Bos JD, et al. Digital image analysis for the evaluation of the inflammatory infiltrate in psoriasis. Archives of dermatological research. 2005;297(2):51–9.PubMedCrossRef Goedkoop AY, de Rie MA, Teunissen MB, Picavet DI, van der Hall PO, Bos JD, et al. Digital image analysis for the evaluation of the inflammatory infiltrate in psoriasis. Archives of dermatological research. 2005;297(2):51–9.PubMedCrossRef
31.
go back to reference Kraan MC, Haringman JJ, Ahern MJ, Breedveld FC, Smith MD, Tak PP. Quantification of the cell infiltrate in synovial tissue by digital image analysis. Rheumatology. 2000;39(1):43–9.PubMedCrossRef Kraan MC, Haringman JJ, Ahern MJ, Breedveld FC, Smith MD, Tak PP. Quantification of the cell infiltrate in synovial tissue by digital image analysis. Rheumatology. 2000;39(1):43–9.PubMedCrossRef
32.
go back to reference Noutsias M, Pauschinger M, Ostermann K, Escher F, Blohm JH, Schultheiss H, et al. Digital image analysis system for the quantification of infiltrates and cell adhesion molecules in inflammatory cardiomyopathy. Med Sci Monit. 2002;8(5):MT59-71.PubMed Noutsias M, Pauschinger M, Ostermann K, Escher F, Blohm JH, Schultheiss H, et al. Digital image analysis system for the quantification of infiltrates and cell adhesion molecules in inflammatory cardiomyopathy. Med Sci Monit. 2002;8(5):MT59-71.PubMed
33.
go back to reference Sont JK, De Boer WI, van Schadewijk WA, Grunberg K, van Krieken JH, Hiemstra PS, et al. Fully automated assessment of inflammatory cell counts and cytokine expression in bronchial tissue. American journal of respiratory and critical care medicine. 2003;167(11):1496–503.PubMedCrossRef Sont JK, De Boer WI, van Schadewijk WA, Grunberg K, van Krieken JH, Hiemstra PS, et al. Fully automated assessment of inflammatory cell counts and cytokine expression in bronchial tissue. American journal of respiratory and critical care medicine. 2003;167(11):1496–503.PubMedCrossRef
34.
go back to reference Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008;14(23):7798–803.CrossRef Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008;14(23):7798–803.CrossRef
35.
go back to reference Fischer L, Kleeff J, Esposito I, Hinz U, Zimmermann A, Friess H, et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg. 2008;95(5):627–35.PubMedCrossRef Fischer L, Kleeff J, Esposito I, Hinz U, Zimmermann A, Friess H, et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg. 2008;95(5):627–35.PubMedCrossRef
36.
go back to reference Pape UF, Jann H, Muller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008;113(2):256–65.PubMedCrossRef Pape UF, Jann H, Muller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008;113(2):256–65.PubMedCrossRef
37.
go back to reference Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez JA, Martinez Del Prado MP, Alonso Orduna V, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010;21(9):1794–803.PubMedCrossRef Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez JA, Martinez Del Prado MP, Alonso Orduna V, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010;21(9):1794–803.PubMedCrossRef
38.
go back to reference Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. 2010;23(6):824–33.PubMedCrossRef Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. 2010;23(6):824–33.PubMedCrossRef
Metadata
Title
Comparison of Three Ki-67 Index Quantification Methods and Clinical Significance in Pancreatic Neuroendocrine Tumors
Authors
Trynda N. Kroneman
Jesse S. Voss
Christine M. Lohse
Tsung-Teh Wu
Thomas C. Smyrk
Lizhi Zhang
Publication date
01-09-2015
Publisher
Springer US
Published in
Endocrine Pathology / Issue 3/2015
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-015-9379-2

Other articles of this Issue 3/2015

Endocrine Pathology 3/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.